Possible explanations are either that the associations of anemia with CKD and HF prognosis do not reflect direct causality but residual confounding or reverse causality, or the use of EPO/ESA increases risk through other side effects outside of erythropoiesis [121]. This evidence concerns the gene EPO and chronic kidney disease.